Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.36 as of 2026-09-15T14:21:21.023Z.
Consensus retrieved: 2026-09-13T22:56:56.477Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-15T14:21:21.023Z.
Quote observation: 2026-09-15T14:20:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fff3b66753df9103aa6e8fa6e6867ea0bbba62446faea70668aaa7a177e0f800
Forward PE Ratio (14.36) = Dated Quote Price ($423.30) / Consensus Forward EPS ($29.47)
FORWARD PE RATIO
14.36
SECTOR MEDIAN · HEALTHCARE
19.26
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-25.44%
vs the sector median at left
HCA Healthcare, Inc.
Market Cap
$91.65B
Forward PE Ratio
14.36
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| HCA Healthcare, Inc. (HCA) | $91.65B | 14.36 |
| Elevance Health Inc. (ELV)vs › | $91.35B | 15.52 |
| GSK plc (GSK)vs › | $99.91B | N/A |
| Sanofi (SNY)vs › | $102.58B | N/A |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $79.94B | 14.24 |
| McKesson Corporation (MCK)vs › | $104.88B | 20.07 |
| Stryker Corporation (SYK)vs › | $106.75B | 18.55 |
| Cigna Corporation (CI)vs › | $76.31B | 9.47 |
| Boston Scientific Corporation (BSX)vs › | $65.40B | 13.38 |
| Medtronic plc (MDT)vs › | $119.47B | 15.62 |
Trailing P/E
14.2
reported TTM EPS
Forward P/E
14.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $29.47 implies -1.3% EPS decline vs the reported trailing $29.87.
At the dated quote price of $423.30, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $29.47 | $29.14 – $30.07 | 15 | 14.4x |
| 2027-12-31 | $32.09 | $30.34 – $34.04 | 15 | 13.2x |
| 2028-12-31 | $35.34 | $32.94 – $38.50 | 12 | 12.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
